Sai Parenteral’s Ltd (Avoid)

Highlights

Sai Parenteral’s Limited (SPL), incorporated in 2001, is a diversified pharmaceutical formulations company with capabilities in research, development, and manufacturing. They are in the business of (i) (i) branded generic formulations and (ii) contract development and manufacturing organization (CDMO) products and services for the domestic and international markets.

Their portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.

SPL manufactures and sells branded generic formulations to a diverse customer base, including central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in the domestic market, and they export their products to the regulated and semi-regulated markets of Australia, New Zealand, Southeast Asia, the Middle East, and Africa through distributors.

Out of the total proceeds of Rs. 4,090 mn from the offer, ~Rs. 1,108 mn would go towards capacity expansion and upgradation of manufacturing facilities, and Rs. 180 mn would go towards the establishment of a new R&D facility. Rs. 499 mn would be utilized towards repayment of outstanding borrowings. Rs. 330 mn would go for working capital requirements, ~Rs. 732 mn would go towards general corporate purposes, and Rs. 1240 mn would go towards existing selling shareholders of the company.

Key Highlights

• The Indian pharmaceutical industry is the world’s third largest by volume and was estimated at USD 62 bn in 2025. It is expected to grow at a CAGR of 11.2 pct to reach USD 146 bn by 2033. The Indian drug formulation market, estimated at ~USD 47 bn in 2025, is projected to reach USD 109 bn by 2033, reflecting a robust CAGR of 11.2 percent over the period. The Indian CDMO segment is to sustain its strong growth trajectory over the next 10 years.

• They own and operate 5 manufacturing facilities in India. In order to capture the growing demand for specialized products, SPL intends to expand and upgrade their facilities by almost double capacity. Their Unit IV facility is under development and is expected to be completed by Q4CY26. An AUD 20 mn grant has already been disbursed by the Australian Government for this project.
• SPL’s revenue mix has evolved over the years to reflect their broader operations. Over the past 3 years their share of sales of CDMO products & services has grown significantly. This diversification has helped them reduce segment-specific risks and adapt to changing market demand and trends. During this period of growth and diversification, they have focused on operating efficiently and maintaining profitability across their business and product segments.
• SPL has an established presence in the institutional markets; their institutional business spans multiple Indian states, contributing to growing visibility and recognition within this segment. They participate in procurement tenders issued by central and state government agencies for the supply of both high-value and high-volume pharmaceutical formulations. And SPL supplies to various state procurement agencies, as well as to multiple locations under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana and ESI hospitals across India.
• The company’s key strategies include (i) expansion into the global injectable formulations market. (ii) Capitalize on the CDMO opportunity by leveraging manufacturing capabilities with enhanced R&D competencies. (iii) Strengthening presence in regulated markets through the upcoming Noumed manufacturing facility at Adelaide, Australia. (iv) Focus on new product development to drive future growth. (v) Grow the Branded Generic Formulations business by leveraging opportunities in the international markets. (vi) Expand capabilities through strategic acquisitions.
• Sales of the company have grown by 29.8 pct CAGR over FY23-25, and EBITDA and profit grew by 49.5 pct CAGR and 81.7 pct CAGR over the same period. During FY25 the sales of the company rose by 6.1 pct YoY to Rs. 1,631 mn. While EBITDA of the company grew by 24.2 pct YoY to Rs. 394 mn and EBITDA margin expanded by 356 bps to 24.18 pct YoY in FY25. During FY25, the company reported a profit of Rs. 145 mn, which grew 71.8 percent YoY.

Key Risk

• SPL’s manufacturing facilities are subject to periodic inspections and audits by regulatory authorities and customers. They may be subject to regulatory action, which may damage their reputation, leading to an adverse effect on their business.
• SPL is exposed to the risk of blacklisting by government authorities, which could prevent them from bidding for government tenders. Any such action could have a disproportionate adverse impact on SPL’s business.

• SPL and their material subsidiary are involved in certain proceedings initiated by regulatory authorities alleging manufacture or sale of substandard quality products. Any adverse outcome in such proceedings may result in penalties or damage to SPL’s reputation.

Financial Performance

Peer Comparison

Valuation

SPL is a diversified pharmaceutical formulations company with capabilities in research, development, and manufacturing. They are in the business of (i) (i) branded generic formulations and (ii) contract development and manufacturing organization (CDMO) products and services for the domestic and international markets. At the upper end of the price of Rs. 392, the issue quotes a PE of 111x on FY26 annualized earnings. The issue looks overpriced. One can avoid this issue.

Disclaimer: The views shared in blogs are based on personal opinions and do not reflect the company’s views. Investment involves risk, and it is advisable to consult a financial advisor before making any investment through the app. The decision to invest is solely that of the investor, and the company or its communication cannot be held responsible for it.